HM-2002 / Shanghai CirCode Biomed - LARVOL DELTA

First-in-Human Pilot Study of Epicardial Circular RNA-HM2002 Injection in CABG for Ischemic Heart Failure (clinicaltrials.gov) - P1 | N=3 | Completed | Sponsor: Ruijin Hospital | Active, not recruiting ➔ Completed | Trial completion date: Sep 2025 ➔ May 2025

First-in-human • Trial completion • Trial completion date • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Heart Failure

Study of the Safety and Tolerability of Circular RNA-HM2002 Injection for Ischemic Heart Disease (ChiCTR) - P1 | N=9 | Recruiting | Sponsor: Ruijin Hospital, Shanghai Jiao Tong University School of Medicine; Ruijin Hospital, Shanghai Jiao Tong University School of Medicine

New P1 trial • Cardiovascular • Coronary Artery Disease • Heart Failure • MB

CirCode Biomed Announces FDA Clearance for IND Application of HM2002, the world's first circular RNA drug being administrated in patients (ACROFAN) - "Shanghai CirCode Biomed Co. Ltd...recently announced that its leading pipeline HM2002 received Investigational New Drug (IND) clearance from the US Food and Drug Administration (FDA) for ischemic heart disease on May 30, 2025."

IND • Cardiovascular • Coronary Artery Disease

First-in-Human Pilot Study of Epicardial Circular RNA-HM2002 Injection in CABG for Ischemic Heart Failure (clinicaltrials.gov) - P1 | N=3 | Active, not recruiting | Sponsor: Ruijin Hospital | Recruiting ➔ Active, not recruiting

Circular RNA • Enrollment closed • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Heart Failure